Cargando…

Risk of Nonmelanoma Skin Cancers and Parkinson’s Disease—Meta-Analysis and Systematic Review

SIMPLE SUMMARY: Non-melanoma skin cancers (NMSCs) are the most common cancers among fair-skinned people. It is estimated that 2–3 million new cases of NMSCs are diagnosed globally each year. The risk of development increases with age, just like in the case of Parkinson Disease. Due to the general ag...

Descripción completa

Detalles Bibliográficos
Autores principales: Krasowska, Danuta, Gerkowicz, Agnieszka, Mlak, Radosław, Leziak, Milena, Małecka-Massalska, Teresa, Krasowska, Dorota
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913207/
https://www.ncbi.nlm.nih.gov/pubmed/33546132
http://dx.doi.org/10.3390/cancers13040587
Descripción
Sumario:SIMPLE SUMMARY: Non-melanoma skin cancers (NMSCs) are the most common cancers among fair-skinned people. It is estimated that 2–3 million new cases of NMSCs are diagnosed globally each year. The risk of development increases with age, just like in the case of Parkinson Disease. Due to the general aging of the population and substantially high medical costs of NMSC therapy, NMSCs and Parkinson’s disease (PD) are becoming an increasing health problem. In this paper, we conduct a meta-analysis and systematic review to evaluate the NMSC risk among patients with PD. This study is the first to focus on the effect of different epidemiologic aspects of NMSCs and PD in detail. ABSTRACT: Patients with Parkinson’s disease (PD) have an increased risk of melanoma compared with the general population. Considering that Nonmelanoma Skin Cancers (NMSCs) share similar risk factors with melanoma, there is a need to understand a possible connection between PD and NMSCs. The aim of the study was the evaluation of NMSC risk among PD patients via meta-analysis and systematic review. A comprehensive search of PubMed, Scopus, and Web of Science databases was conducted, including studies from January 2000 to April 2020. We identified 16 eligible studies including 140291 PD patients. Upon statistical analysis, a significantly higher risk of developing NMSCs in PD patients was found compared with the control group (odds ratio (OR) = 1.25, 95% CI: 1.17–1.33; p < 0.0001). Among all NMSCs, the risk of developing basal cell carcinoma in PD patients was significantly higher (OR = 1.30, 95% confidence interval (CI): 1.15–1.47; p < 0.0001), contrary to squamous cell carcinoma. Further analysis revealed a significantly higher risk of developing NMSCs in patients with previously diagnosed PD (OR = 1.26, 95% CI: 1.19–1.33; p < 0.0001). Our data suggest the necessity for regular skin examination of PD patients, though further studies are required to explore the mechanisms forming this relationship.